Beam Therapeutics Inc.
BEAMNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $139.7M | $63.5M | $377.7M | $60.9M | $51.8M | $24,000 |
| Operating income | −$383.7M | −$415.6M | −$176.5M | −$338.5M | −$392.5M | −$132.8M |
| Net income | −$80.0M | −$376.7M | −$132.5M | −$289.1M | −$370.6M | −$194.6M |
| Total assets | $1.48B | $1.10B | $1.46B | $1.34B | $1.47B | $451.7M |
| Total liabilities | $242.8M | $370.3M | $478.4M | $608.2M | $647.7M | $206.1M |
| Equity | $1.24B | $733.5M | $981.3M | $733.5M | $826.7M | $245.6M |
| EPS (diluted) | $-0.81 | $-4.58 | $-1.72 | $-4.13 | $-5.77 | $-4.19 |
| Shares out. | 83.7M | 81.7M | 72.4M | 68.7M | 62.4M | 57.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −274.6%
- Net margin
- −57.2%
- Return on equity
- −6.5%
- Return on assets
- −5.4%
- Return on capital (ROCE)
- −27.7%
- Liabilities / assets
- 16.4%
- Debt / equity
- 0.20×
- Book value / share
- $14.80
- Revenue growth (YoY)
- 120.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 5.19safe
- Accruals / assets
- 17.9%high accruals
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 4 warning● 3 good- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- High accruals — earnings-quality risk
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Recruitingreadout ~2026-01-29This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjects
- Phase 1/2Active Not Recruitingreadout ~2026-12A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
- Phase 1/2Recruitingreadout ~2027-12-30A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)
- Phase 1/2Active Not Recruitingreadout ~2028-02BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease
- Phase 1/2Recruitingreadout ~2028-05A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vanguard Capital Management LlcPassive (13G)Apr 29, 2026
- Vanguard Group IncPassive (13G)Mar 26, 2026
- State Street CorpPassive (13G)Feb 9, 2026
- Farallon Capital Partners, L.P.Passive (13G)Feb 5, 2026
- Fmr LlcPassive (13G)Feb 5, 2026
- Ark Investment Management LlcPassive (13G)Feb 3, 2026
- Arch Venture Fund Ix, L.P.Passive (13G)May 15, 2025
- Blackrock, Inc.Passive (13G)Apr 17, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 26.5M | 12.6 | +26.6% |
| Apr 30, 2026 | 20.9M | 9.5 | -5.8% |
| Apr 15, 2026 | 22.2M | 11.1 | -4.9% |
| Mar 31, 2026 | 23.4M | 10.7 | +9.7% |
| Mar 13, 2026 | 21.3M | 10.6 | -2.7% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 7, 2026
- Terminated a material agreementMar 5, 2026
- Entered a material agreement · Results of operations · New financial obligationFeb 24, 2026
- Entered a material agreementFeb 12, 2026
- Director / officer changeFeb 5, 2026
- Results of operations · Regulation FD disclosureJan 12, 2026
- Completed an acquisition or dispositionDec 11, 2025
- Results of operationsNov 4, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.